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Feasibility of polymer-drug conjugates for non-cancer 
applications 
 
Az Alddien Natfji, Helen M. I. Osborn, Francesca Greco1 
Reading School of Pharmacy, University of Reading, Whiteknights, Reading, RG6 6AD, UK.  
 
Abstract:  
Polymer-drug conjugates have been intensely studied in the context of improving cancer 
chemotherapy and yet the only polymer-drug conjugate on the market (MovantikÒ) has a 
different therapeutic application (relieving opioid-induced constipation). In parallel, a number 
of studies have recently been published proposing the use of this approach for treating 
diseases other than cancer. In this commentary, we analyse the many and very diverse 
applications that have been proposed for polymer-drug conjugates (ranging from 
inflammation, to cardiovascular diseases) and the rationales underpinning them. We also 
highlight key design features to be considered when applying polymer-drug conjugates to 
these new therapeutic areas. 
Keywords: non-cancer disease, polymer-drug conjugate, macromolecular prodrug, EPR effect, 
targeted drug deliver, inflammation, cardiovascular diseases.   
List of abbreviations: AHPP: 4-amino-6-hydroxypyrazolo[3,4-D]pyrimidine; Apaf-1: Apoptotic 
protease activating factor 1; AsnPhePhe: Asparagine-phenylalanine-phenylalanine; D-(Asp)8: D-Aspartic 
acid peptide; D: Degradable (E: Enzymatic degradation; H: Hydrolytic degradation); EDTA: 
Ethylenediaminetetraacetic acid; G: Generation; GFAL: Glycine-phenylalanine-alanine-leucine; GFGG: 
Glycine-phenylalanine-glycine-glycine; GFLG: Glycine-phenylalanine-leucine-glycine; GG: Glycine-
glycine; 4G Glycine-glycine-glycine-glycine; GGPNle: Glycine-glycine-proline-norleuicne; GL: Glycine-
leucine; HEMA: 2-hydroxyethyl methacrylate; HPMA: N-(2-hydroxypropyl)methacrylamide; I/R: 
ischemia reperfusion; Lact2G: Lactic acid-glycine-glycine; Lact4G: Lactic acid-glycine-glycine-glycine-
glycine; LMHC; low molecular weight hydroxyethyl chitosan; N/A: Not applicable/Not stated; OR: 
Oxidation responsive; PAA: Poly(acrylic acid); PAHA: Poly[α,β-(N-2-hydroxyethyl-DL-aspartamide)]-
poly[α,β-(N-2-aminoethyl-DL-aspartamide)]; PAMAM: Poly(amidoamine); PCL: Polycaprolactone; 
pDMAEMA: Poly(dimethylamino)ethyl methacrylate; PEG: Poly ethylene glycol; mPEG: methoxy PEG; 
sPEG: star PEG; PGA: Polyglutamic acid; PHEA: α,β-poly [(N-2-hydroxyethyl)-DL-aspartamide]; PHPA: 
Poly[α,β- (N-3-hydroxypropyl-DL-aspartamide)]; PHPMA: Poly N-(2 hydroxypropyl)methacrylamide; 
PMAA: Poly(methacrylic acid); PVP: Poly(vinylpyrrolidinone); SMA: Styrene-maleic acid. 
1. Introduction 
Pioneering work on polymer-drug conjugates (PDC)s started in the 1950s [1*], but it was 
only in 1975 that the concept of PDC as a means of achieving drug targeting was formalised 
by Ringsdorf [2**]. Since then, research in this field has traditionally focussed on their 
applications in cancer to enhance the delivery of chemotherapeutic agents to tumour tissues. 
Interestingly, whilst a number of conjugates progressed to clinical trials with some reaching 
Phase 3 [3**,4], the only polymer-drug conjugate on the market (PEG-naloxone, naloxegol, 
MovantikÒ) is actually used for a different therapeutic application (to treat opioid-induced 
constipation) [5]. PEG-naloxone is a conjugate in which a PEG oligomer (7 units, MW of <1 
kDa) and drug molecules (naloxone) are covalently attached via a linker [6]. However, the 
rationale for this system (and its subsequent application) is fundamentally different from that 
of traditional polymer-drug conjugates (see Fig. 1). For example, in traditional polymer-drug 
conjugates the purpose of the polymer is to increase selective accumulation in the tumour 
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through passive accumulating in the tumour tissue, by the enhanced permeability and 
retention effect (EPR) [7**,8]. In MovantikÒ, however, the PEG is incorporated to prevent 
naloxone from penetrating through the blood-brain barrier, hence maximising its peripheral 
effects [5].  
Whilst many reviews focus on the use of polymer-drug conjugates for cancer, the 
application of polymer-drug conjugates for non-cancer diseases has been less widely 
reviewed  [9**,10]. This review therefore critically appraises the application of PDCs in 
diseases other than cancers, with a focus on the rationales and the key considerations that 
have underpinned their design (Tables 1 and 2), with information summarised according to 
the therapeutic area. We finish the commentary with some general considerations about this 
emerging field. 
 
2. Polymer-drug conjugates in diseases other than cancer 
The strategy of conjugating low molecular weight drugs to polymeric carriers has been 
applied in order to develop novel therapeutic systems towards diseases other than cancer. 
These applications include infections, inflammation, nervous system diseases, cardiovascular 
disease, endocrine disease, digestive diseases, bone problems, eye diseases, and wound-
related problems as summarised in Table 2. In these cases, PDCs have generally been 
developed in order to overcome limitations associated with therapeutically active drugs that 
are typically used in these diseases, for example poor solubility, undesirable pharmacokinetic 
properties, or low bioavailability at the disease site.  
 
2.1. Polymer-drug conjugates as polymer therapeutics for infections 
2.1.1.  Antibiotics:  
PDCs of different antibacterial agents have been developed in order to enhance their 
therapeutic activity against different types of bacteria, as summarised in Table 2. Three main 
aims were explored in these studies, specifically: a) to provide a sustained release of the drug 
which led to a reduced toxicity, b) to selectively target the drug to the desired site of action, 
c) to extend the t1/2 of the drug. The first studies in this area were reported in the 1960s where 
water-soluble polymeric derivatives of various penicillin antibiotics using 
polyvinylpyrrolidone were developed [25–27]. Later, in a study reported in 1989, the aim 
was to reduce toxicity associated with the administration of isoniazid against Mycobacterium 
tuberculosis by developing a system for the sustained release of isoniazid. Isoniazid was 
linked via an amide bond to poly-α,β aspartic acid [12] and to poly(DL-succinimide) [13]. The 
poly(DL-succinimide)-isoniazid conjugate exhibited delayed release of the isoniazid in the 
simulated gastric environment pH (1.2) due to the gradual degradation of the amide linkage 
in vitro [13]. A similar approach was used also for Peptoid 7, a small molecule with an ability 
to neutralise lipopolysaccharides and potentially treat septicaemia, to provide a controlled 
release of this drug and again to improve its safety profile [15]. Peptoid 7 was linked to PGA 
and PEG via different spacers: the dipeptide GG with or without lactic acid (Lact) through 
amide and ester bonds, respectively. In vitro release studies indicated that the conjugates 
were stable plasma, but released the drug after exposure to cathepsin B.  
The second rationale for employing conjugation was to enhance the targeting of antibiotics 
to specific cells and tissues depending on different mechanisms. Azithromycin was linked via 
an ester bond to a PAMAM G4 dendrimers to increase the delivery of azithromycin and to 
improve its antibacterial activity against Chlamydia trachomatis [21]. The design of the 
conjugate was based on the ability of dendrimers to accumulate in inflamed tissues (such as 
chlamydial arthritis) due to the leaky vasculature of the area. This  allows accumulation of 
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macromolecules which is enhanced further as a result of the dendrimer’s affinity for 
glucosaminoglycan released in the inflamed tissues [28–31]. In vitro studies indicated high 
uptake of the fluorescently-labelled azithromycin dendrimers by the Chlamidya trachomatis 
infected human epithelial type 2 (HEp-2) cells in both acute and persistent states of infection 
with high localisation of the dendrimers in the inclusions.  
In other studies, selective accumulation at the infected site was achieved by using targeting 
moiety rather than exploiting the natural accumulation of the systems in the tissues. As 
mannose receptors are expressed on the surface of the macrophages [32], conjugates of  
norfloxacin were grafted with mannose moieties to increase accumulation in macrophages 
infected by Mycobacterium tuberculosis bacilli. The effectiveness of the strategy was the 
proven in vivo (M.Bovis BCG infected mice), where, unlike the non-mannosylated conjugate, 
the mannosylated conjugate was effective against isoniazid-insensitive mycobacteria in the 
liver, spleen, and lung [17,18]. Other targeting ligands have been suggested such as a 
carboxymethylation of glucan to target T.B infected macrophages [19]. One particularly 
interesting example of actively targeted conjugate is PAMAM (G3)-LED209 for Gram 
negative bacterial infection. In this case, LED209 had a dual role as an active drugs and as a 
targeting ligand [20]. The mechanism of action of LED209 is based on the allosteric 
alteration of lysine residues of QesC which, consequently, impairs the function of QesC and 
significantly reduces the virulence of the pathogens. QesC is a histidine sensor kinase that is 
found in at least 21 Gram negative bacteria that induce infection in humans and also plays an 
important role in activating the expression of the virulence genes in these pathogens. 
Moreover, LED209 does not display toxicity and does not influence the bacterial growth 
[33]. In vitro analysis demonstrated greater accumulation of the LED209-dendrimers in the 
bacteria cells than in mammalian SW480 cells. Furthermore, G3 PAMAM-LED209 
significantly inhibited the expression of virulence genes in EHEC and S. typhimurium, and 
displayed potent antibacterial activity against susceptible and resistant Gram negative 
bacteria.  
The third rationale for applying a PDC strategy for antibacterial usage was to address 
unfavourable pharmacokinetic properties of certain antibiotics. For instance, vancomycin is a 
glycopeptide antibiotic that requires infusion every 6 hours to obtain effective therapeutic 
levels due to renal elimination (t1/2 of 4.8 h) [34]. PEG-vancomycin conjugates were prepared 
to increase the mean residence time of the drug in the blood stream by reducing the renal 
excretion with a size exclusion mechanism [23]. All conjugates showed antibacterial activity 
against S. aureus in infected mice. Furthermore, all conjugates exhibited high AUC with a 
range of 171-2184 h.µg/mL in comparison with native vancomycin (78.8 h.µg/mL), which 
indicated that the conjugate might require less frequent administration than the free drug. 
 
2.1.2. Antifungal 
The rationales behind the application of a conjugation strategy within the context of 
treating fungal infections are mainly to reduce the toxicity of the drug by increasing water 
solubility, and/or to enhance the selective drug targeting to the fungal infected tissues and 
increase drug accumulation (which is based on the specific environmental pH of the infected 
tissues and on a fungi specific enzyme which mediates release of the drug, Table 2). 
Amphotericin B and nystatin are antifungal drugs [44] whose applications are limited by poor 
water solubility and other unfavourable characteristics (high nephrotoxicity for amphotericin 
B; low gastrointestinal absorbance and toxicity for nystatin).  
 In order to improve water solubility, it was important to select highly hydrophilic 
polymeric carriers, and, indeed, a natural polysaccharide (arabinogalactan) was used for this 
purpose in most studies that aimed to improve water solubility [35,37,39]. The remaining 
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studies used another common water-soluble polymer (PEG) [36,38]. The solubility of 
amphotericin B was highly improved after polymer conjugation (200 - 2000 folds increase 
for arabinogalactan conjugates and 140-250 folds for PEG conjugates). An increase in 
solubility is particularly important for amphotericin B because its physical characteristics, in 
particular its tendency to self-assemble, have been associated with nephrotoxicity [45]. 
Indeed, systems, such as liposomal formulations of this drug, are significantly less toxic than 
the native one (eg. AmBisome® is about 50 times less toxic in vivo than Fungizone® [46,47]). 
Similarly, conjugation to a polymer, and subsequent increase in water solubility also led to a 
decrease in the toxicity of amphotericin B [48]. The decrease in toxicity depended on the 
linker, which presumably correlates with the rate of drug release rate. For instance, when 
amphotericin B was conjugated to arabinogalactan through an amine or imine linkage 
[35,37], the latter was the least toxic and did not cause any measurable damage to the kidney 
in vivo.  
The second rationale for using PDCs with antifungals was to improve targeting of fungal 
infected tissues. The targeting strategy relied on selective drug release, promoted by either 
the acidic pH of the infected tissues, or by the presence of a specific hydrolytic β-glycosidase 
enzyme which is found in pathogenic fungi but not human tissues [49]. For these purposes, 
amphotericin B was linked to PEG via a pH labile linker (typically an imine linker) [41]. The 
conjugates were relatively stable when challenged in human physiological fluids (blood, 
serum, or/and plasma) with a t1/2 of 2-5 h, while at pH 5.5 the t1/2 was 2 min. The enzymatic 
targeting strategy was employed using β-glycosidase labile linkers. Conjugates of 
amphotericin B and of nystatin were synthesised containing this type of linkers. The strategy 
proved successful as both conjugates were stable in phosphate buffer at pH 7.4 in vitro, while 
drug release was observed in the presence of the enzyme [42,43*]. 
 
2.1.3. Antiviral 
The concept of macromolecular prodrugs has been widely applied to improve the 
therapeutic effects of several antiviral drugs by focusing on: a) improving the water solubility 
and providing controlled drug release; b) prolonging the antiviral activity by extending the 
t1/2; c) enhancing the selective drug targeting of the virally infected tissues; and d) reducing 
unwanted cellular interactions. Examples of these systems are presented in this section and 
are summarised in Table 2. 
The conjugation to a hydrophilic carrier was employed to improve the therapeutic activity 
of acyclovir, an antiviral agent used against herpes simplex type I/II, by improving its water 
solubility and offering controlled release [57]. In this study, β-cyclodextrin was used for 
conjugating acyclovir through an ester bond. The solubility of acyclovir was increased two-
fold after the conjugation. In vitro hydrolysis studies at different pHs and in the presence or 
absence of esterase showed that drug release was affected by the conditions (100% drug 
release in presence of esterases). Similarly, a PDC strategy was applied to another reverse 
transcriptase inhibitor – stavudine – in order to achieve a delayed drug release and reduce its 
metabolism, and consequently, prolong its t1/2. Chitosan was covalently linked to stavudine 
[54,55] and the conjugate was used to prepare nanoparticles.  In vitro release studies of both 
the conjugate and nanoparticles revealed that prolonged release of the drug was provided by 
both systems. This prolonged release profile enhanced the anti HIV activity by enabling the 
stavudine to bypass the rate limiting step of metabolic monophosphorylation. Interestingly, 
the conjugate was 13 times less toxic than the free drug, which could suggest, in addition to 
extending drug release, that the conjugate masked the toxicity of the drug.  
Polymeric systems were also developed to enhance the t1/2 of zidovudine, a reverse 
transcriptase inhibitor used for HIV treatment, by providing a sustained release of the drug 
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and decreasing its renal elimination depending on the MW of the polymers 
[50,56,58,61,62,69,70]. Dextrin (MW 6600 g/mol) was used for the conjugation with 
zidovudine for this purpose [62]. In vivo studies showed that the strategy worked in that 
conjugation increased the t1/2 of zidovudine after i.v administration from 1.3 to 19.3 h due to 
the effect of dextrin’s high MW on the renal filtration. It is important to mention that, in 
addition to extend the t1/2, some polymers were used also to produce a synergistic antiviral 
effect with zidovudine. Thus sulfated laminaripentaose and κ-carrageenan conjugates of 
zidovudine showed enhance antiviral activity compared to the free drug [56,70].  
Selective targeting of virally infected tissues is another reason for which developing PDCs of 
antivirals has been suggested. In this context, most studies reported the use of a targeting 
moiety to promote receptor-mediated internalisation of the antiviral agent. Examples include 
the use of biotin and R.I.CK-Tat 9 (a peptide which contains D-aminoacids in the inverse 
order of the natural L-peptide, thus ensuring better stability) for HIV [63,64]; lactobionic acid 
for HBV; [65]; and lactosamine for HCV [66]. For example, lamivudine, an anti-hepatitis B 
agent, was conjugated to chitosan grafted with lactobionic acid which can enhance hepatic 
targeting [65]. Interestingly, the presence of lactobionic acid enhanced the hepatic targeting 
and cellular uptake of lamivudine. Furthermore, the addition of lactobionic acid resulted in 
improved solubility and reduction in toxicity. A similar concept was employed for saquinavir  
which was the first approved FDA HIV-1 protease inhibitor [75]. A library of saquinavir 
polymeric conjugates based on PEG was prepared using biotin or R.I.CK-Tat 9 as a targeting 
ligand. The design of these systems allowed the use of the targeting ability of biotin and 
R.I.CK-Tat 9  and their anti HIV activity.[63,64]. In vitro studies indicated that the addition 
of biotin to the conjugates increased their antiviral activity, and a further increase in the 
activity was noticed upon replacing biotin with R.I.CK-Tat 9 (a peptide with cell penetrating 
properties [76]). Importantly, the anti-HIV-1 activity of PEG-R.I.CK-Tat 9- saquinavir 
conjugate was similar to that of saquinavir, and the cytotoxicity of the conjugate was lower 
than that of saquinavir against non-infected MT-2 cells.  
The macromolecular prodrug strategy was also used to improve the therapeutic 
applications of ribavirin by reducing its administration-associated toxicity. Ribavirin is a 
broad-spectrum antiviral used particularly in hepatitis C. However, it exhibits a dose 
dependent-toxicity due to its accumulation in red blood cells [77]. To improve the toxicity 
profile of ribavirin, a conjugate with poly(acrylic acid) was developed that incorporated an 
ester linkage [71*]. In vitro studies indicated that conjugation reduced the ability of the 
ribavirin to accumulate in red blood cells, which, in turn, led to a significant decrease in its 
toxicity.  
 
2.1.4. Antiprotozoal agents 
Leishmaniosis and malaria are parasitic diseases that are induced by the intracellular 
protozoans of the genus Leishmaniosis and Plasmodium parasites and transmitted by 
Anopheles mosquitoes [86,87]. Interestingly, in the case of leishmaniosis, the idea of 
applying PDCs within this concept was based on the similarity observed between the parasite 
organelles and human lysososomes, which share the same acidic pH and proteolytic enzymes 
such as cathepsins B, D, and H [83]. PDC had been proven to be able to target human 
lysosomes in their applications for cancer [88],Therefore, it was hypothesised that PDCs 
could improve the targeting of the drug to the parasite infected cells (Table 2).  
Amphotericin B has already been discussed in section 2.1.2 (antifungals), however, this 
drug is also an effective antileishmanial agent [89]. Conjugation of amphotericin B to 
polymers has therefore also been explored to target amphotericin B to the location of 
parasites in the host macrophages. There was also scope for active targeting as the 
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leishmanial parasites have cell surface glycoproteins that mainly contain mannose residues 
[90], which enhance their uptake by hepatic macrophages via mannose receptors [91]. 
Therefore, amphotericin B was conjugated to an (HPMA) copolymer via a cathepsin labile 
peptide linkage with or without mannosamine. The conjugates exhibited antileishmanial 
activity against intracellular L. donovani amastigotes in the tested host macrophages cells in 
vitro. Their activity was of the same magnitude as free amphotericin B as well as 
Fungizone®. In vivo studies in infected BALB/c mice indicated the ability of the pHPMA-
GFLG-amphotericin B conjugate to inhibit the parasite burden in levels similar to that of the 
AmBisome®. However, there was no significant impact of linking mannosamine residues to 
the conjugate on its antileishmanial activity.  
The conjugation concept was also used to prolong the therapeutic activity of drugs. 
Primaquine (a quinolone analogue) is an antimalarial agent that is effective against different 
types of malaria [92]. However, its clinical applications are limited by its rapid metabolism to 
carboxyprimaquine (t1/2: 4-9 h), and toxicity [93]. To overcome these limitations, primaquine 
was covalently conjugated through a carbamate linkage to two types of polyaspartamide 
polymers (PHEA and PHPA). The conjugation reduced the metabolism of primaquine [80]. 
In vivo studies in mice demonstrated that PHEA and PHPA conjugates (administered orally) 
exhibited prolonged antimalarial activity (for +28 days) against Plasmodium. berghei.  
The strategy of combination therapy using PDCs was employed to improve the 
therapeutic activity of both antimalarial agents primaquine and dihydroartemisinin 
(artemisinin analogue, a novel antimalarial agent [94]). They were covalently linked to 
polyphosphazene (a synthetic polymer), and nanoparticles of the conjugates were prepared to 
enhance the delivery of the drugs to the hepatic tissues. In vivo studies indicated that all 
formulations at low doses displayed antimalarial activity against P. berghei (NK 65) infected 
mice that was comparable to that of the free drugs, and the protection activity lasted without 
any recrudescence for more than 35 days [85]. 
 
2.2. Polymer-drug conjugates as polymer therapeutics for inflammation 
The concept of conjugation has been widely applied within the context of inflammation 
and other related diseases (Table 2). This is a particularly interesting therapeutic application, 
because the rationale for using polymer-drug conjugates in inflammation stems from 
similarities in the pathophysiological features of the inflamed tissue (such as rheumatoid 
arthritis) and those of cancer. Specifically, the key features observed in inflamed tissues 
(increased blood supply to the area with oedema due to the leaky blood vessels [130,131]) are 
reminiscent of the hyperpermeability of tumour vasculature, due to the EPR effect [8,132].  
For this purpose, a copolymer conjugate of dexamethasone and HPMA [133] was prepared 
containing a pH labile (MA-Gly-Gly-NHN= dexamethasone) monomer system to provide 
selective targeting and release of the drug at the site of inflammation based on the EPR-like 
effect and the acidic environment (pH 4.4- 5.6) induced by rheumatoid arthritis [134–136]. In 
vitro studies demonstrated that the release was pH dependent, where no release of the drug 
was detected at pH 7.4, and at pH 5 its release followed zero-order kinetics with 14% of the 
drug being released during the course of the study (14 days).  Moreover, in vivo results 
demonstrated that the conjugate exhibited longer lasting and enhanced joint protection and 
anti-inflammatory effects compared to the free drug. The tropism of some polymeric systems 
towards some tissues or organs was also employed to achieve passive accumulation of the 
conjugated drugs. This was used to develop a PDC for an anti-inflammatory drug, N-acetyl 
cysteine (NAC), that shows promising therapeutic activity for neuro-inflammation but poor 
oral bioavailability associated with a short t1/2. Therefore, it was conjugated to PAMAM (G 
3.5) to improve its delivery to the activated microglial cells (the biological target cells of N-
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acetyl cysteine). The system was based on the ability of PAMAM dendrimers to accumulate 
in these cells (see section 2.1.1), to provide a cytosolic delivery of the drug, and on the 
intracellular hydrolysis of the linker in the presence of glutathione (which is found in very 
low levels in plasma and in high levels inside the cells [137]). In vitro release studies 
indicated that in the presence of glutathione at its intracellular concentration, 45% of N-acetyl 
cysteine was released from PAMAM-(COOH)46-(NAC)18, while no release of NAC was 
detected in the absence or even at the blood levels of glutathione. In addition to that, 
PAMAM dendrimers exhibited rapid accumulation within the cells, and the conjugate 
showed improved anti-inflammatory activity compared to the free drug [121*]. The same 
idea was applied for erythromycin, an antibiotic with promising anti-inflammatory activity 
[22*]. Erythromycin has anti-inflammatory properties, with the ability to concentrate 
preferably in monocyte/macrophages exhibiting a ‘phagocyte-targeted delivery’ feature. 
Moreover, in vitro and in vivo studies indicated that erythromycin inhibited osteolysis and 
orthopaedic wear debris mediated inflammation [138]. However, the delivery of 
erythromycin to the periprosthetic inflammation site without displaying systemic side effects 
is a considerable obstacle. To overcome this problem, erythromycin was conjugated to 
PAMAM G4 via an ester linkage to provide a sustained drug release combined with selective 
targeting to the inflamed tissues. In vitro release studies showed that about 90% of the 
erythromycin was liberated within 10 h of incubation. Importantly, the conjugate was not 
toxic and significantly reduced the generation of NO2- in lipopolysaccharide stimulated RAW 
264.7 cells compared to the free drug. Passive accumulation of polymeric 
carrier/macromolecular dextran in the spleen and liver [139] was used to provide selective 
targeting of immunosuppressive drugs to attenuate the acute rejection of liver transplantation 
in rat models [117*]. In this study, dextran was conjugated to methylprednisolone. In vivo 
studies indicated that after administering a single dose of the conjugate, the mean survival 
time of the treated animals was significantly increased (27.5 days) compared to 10.5 days in 
methylprednisolone-treated animals. A significant decrease in the levels of hepatic injury 
markers (bilirubin, ALP, ALT, and AST) was noticed in comparison to methylprednisolone 
treated or control animals. Moreover, conjugated methylprednisolone significantly reduced 
the rejection activity index, and the hepatic and plasma levels of TNF-a, compared to other 
groups. Another interesting feature present in the inflamed tissue (overproduction of ROS) 
was also elegantly exploited to produce selective drug release at the target site. For instance, 
an oxidation responsive copolymer of an acrylate derivative of naproxen (with a 
phenylboronic ester) was polymerized through the reversible addition-fragmentation chain 
transfer using a PEG chain transfer reagent, and nanoparticles were prepared from the 
conjugates. In vitro release studies showed almost no release of naproxen at pH 7.4, while 
>92% of the drug was released after oxidative activation of the conjugate by H2O2 (an ROS 
that is produced in vivo) [123].  
Active targeting was also employed for the selective delivery of drugs to the site of 
inflammation in order to improve their efficacy and reduce their toxicities. This is based on 
the overexpression of folate receptors in inflammation activated macrophages [140]. 
Therefore, PAMAM G5 was conjugated to methotrexate (anti-inflammatory) and folic acid 
(FA) (as a targeting moiety). In vitro binding studies highlighted that the binding affinity of 
the G5-FA-methotrexate to different tested macrophages was dose and energy-dependent, 
and was blocked by the presence of free folic acid. In vivo studies in adjuvant-induced 
arthritic rats indicated that the conjugates exhibited similar preventive effects to free 
methotrexate at an equivalent dose. Moreover, the conjugate exhibited no spleen toxicity in 
comparison to the free drug [111].  
Combination therapy was another rationale for using PDCs in treating inflammation 
related diseases. Methotrexate was covalently linked to hyaluronic acid (HA, an endogenous 
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polysaccharide) using GFLG and AsnPhePhe as lysosomal enzyme cleavable linkers [113].  
In this study, the development of a system based on HA’s ability to improve the 
viscoelasticity of synovial fluid (a lubricating effect) and on the overexpression of CD44 
receptors on the surface of synovial cells (which mediate the endocytosis of HA). In addition, 
lysosomal targeted release of methotrexate was employed. In vitro studies indicated that 
methotrexate derivatives of GFLG and AsnPhePhe were hydrolysed in the presence of 
cathepsins B, D, and L, which suggested the intracellular release of methotrexate. However, a 
significant reduction in knee diameter (swelling) of rats with arthritis was observed only after 
intra-articular injection of the conjugate with AsnPhePhe.   
The similarities between features observed in the inflamed tissues and in cancer (e.g. EPR-
like effect, presence of specific enzymes or species, the acidic pH, and receptor expression) 
make this application, in our view, a particularly interesting and promising area for further 
study.  
 
2.3. Polymer-drug conjugates as polymer therapeutics for diseases of the 
nervous system  
Polymeric prodrugs have also been used to improve the therapeutic activity of drugs used 
for treating diseases of the nervous system (Table 2). The application of this concept aimed at 
protecting the drugs from the degradation and/or at providing targeted release of the drug at 
the intended site. Therefore, PDCs of L-dopa and dopamine were developed to reduced their 
degradation [141,142,144]. A macromolecular prodrug of L-dopa and PHEA was prepared to 
inhibit the peripheral oxidation of the drug, and to improve its water solubility[141].  
The targeting release strategy using macromolecular systems was also applied to a new 
emerging field within neurodegeneration. Familial amyloid polyneuropathy (FAB) is a type 
of neurodegenerative amyloidotic disease that occurs mainly in the peripheral nervous system 
(PNS) due to a mutation in the transthyretin (TTR) protein which leads to its aggregation in 
the tissues, and formation of fibrils [147]. The tetracycline doxycycline, a neuroprotector, 
effectively decreased standard markers of fibril association and disrupted TTR fibril 
formation [148]. Therefore, a polymeric conjugate of doxycycline was developed to enhance 
the release of the drug at the targeted site as a result of the surrounding acidic environment 
(due to inflammation). The system consisted of PGA as a carrier and the conjugation was 
achieved using amide, ester, or amino acid linkers [143*]. In vitro studies revealed that the 
conjugates were stable in plasma for 24 h and none of them were haemolytic. Interestingly, 
the release of doxycycline was detected from PGA-doxycycline with an ester bond, while no 
doxycycline was released from the conjugate with an amide linkage after incubation for 16 
days. Among the prepared conjugates, PGA-CONH-doxycycline was effective in decreasing 
fibril length and numbers of the most aggressive TTR mutations (TTR Leu55Pro). This effect 
might be due to the synergistic activity of the locally accumulated doxycycline and PGA 
negatively charged carboxyl groups which limit the intramolecular interaction of TTR b-
sheet and induced the disruption of fibrils. It is important to highlight that the release of 
doxycycline was not essential for its activity. In vivo bio-distribution studies revealed the 
renal excretion of PGA-CONH-doxycycline with no specific organ accumulation/toxicity in 
mice with an early stage of FAB.   
With regards to the CNS, an interesting application is the use of PDC, to prevent 
permeability across the BBB, and, consequently, stop unwanted central side effects.  
MovantikÒ was developed to prevent the permeation of naloxol, an opioid antagonist used for 
treating opioid induced constipation, through the BBB, and consequently, reduce its central 
side effect. In this case, naloxol is conjugated to a non-biodegradable PEG (low MW <1000 
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Da) through a non-biodegradable ether bond. This conjugation offered the peripheral 
targeting of opioid receptors after oral administration of the conjugate and prevented the 
permeation of naloxol through the BBB. Clinical studies indicated rapid absorption of the 
conjugate after oral administration (<2 h), with a t1/2 of 6-11 h [145,149].       
Finally, based on the same rationale, a recent study attempted to localise the effect of 
haloperidol (a D2 receptor antagonist used as antipsychotic) on either side of the BBB, while 
retaining affinity for the receptor. The system contained haloperidol that was linked to PEG 
via a non-biodegradable carbamate linker [146*]. It was hypothesised that the size of the 
conjugate would inhibit the passive diffusion of haloperidol through the BBB and, 
consequently, would localise its effect on one side of the membrane. In vitro studies indicated 
high stability of the conjugate in rat plasma, (2% release of haloperidol in 1 week). 
Importantly, the conjugate retained affinity for D2 receptors in membranes of CHO cells. In 
silico calculations showed the conjugate was very likely to be BBB impermeable.  
In summary, the concept of conjugation is now considered as a new and promising 
approach to obtain optimal therapy for NS disorders. It allows the protection of the drug 
against degradation and its sustained release within the inflamed tissues.  Importantly, it also 
enhances the peripheral targeting of specific receptors hence reducing unwanted side effects 
of the drugs by preventing their crossing through the BBB.  
 
2.4. Polymer-drug conjugates as polymer therapeutics for cardiovascular 
diseases 
Several macromolecular prodrugs have been developed for treating diseases associated 
with the cardiovascular system (CV) namely: hypertension, dyslipidaemia, ischemia and 
related problems (Table 2). These systems aim to improve the solubility of the free drug, by 
linking drugs to hydrophilic carriers, offering the benefit of combination therapy, and 
retaining the drugs at their sites of administration.   
The concept of improving the water solubility of drugs by conjugation was used to 
enhance the poor water solubility of 4-amino-6-hydroxypyrazolo[3,4-d]pyrimidine (AHPP). 
This compound is a potent antihypertensive that inhibits xanthine oxidase, and consequently 
reduces the interaction of NO and superoxide O2- (found in elevated levels in patients 
diagnosed with hypertension [157]). However, the main obstacle for its clinical application is 
its poor water solubility. To overcome this limitation, a conjugate of AHPP was produced 
using the copolymer of styrene maleic acid (SMA, SMA-AHPP) [152]. In vitro studies 
indicated the high-water solubility of SMA-AHPP with a saturated concentration in distilled 
water (or physiological saline) of 22 mM, while the free HAPP was insoluble in either 
solution. Free drug release was higher at pH 5.5 (30% /day) than at pH 7.4 (22%/ day). 
Interestingly, oral administration of SMA-AHPP in spontaneously hypertensive rats resulted 
in an extended antihypertensive effect of the conjugate which lasted for at least for 7 days.  
Combining the therapeutic activity of the polymer and the drug was another rationale to 
apply the concept of PDCs for CV diseases. Ischemia reperfusion (I/R) injuries are known to 
induce endothelial tissue damage by the overproduction of free radicals and reducing the 
levels of NO [158]. A macromolecular prodrug of PEG and butanediol mononitrate was 
developed to neutralize the oxidative stress and to normalize the response of blood vessels 
[155]. This system was designed to combine the ability of PEG to suppress the production of 
free radicals with the release of NO from butanediol mononitrate. A range of conjugates were 
prepared using b-glutamic acid as a spacer to produce polymers with dendritic structures and 
increased drug loading.  In vivo studies in male Syrian hamsters with I/R injury indicated a 
significant increase in the flow and viscosity of red blood cells, and in the arteriole diameters 
after the treatment with PEG-butanediol mononitrate. This was accompanied by a significant 
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decrease in the permeability of capillaries and venules compared to controls. Moreover, PEG-
butanediol mononitrate induced a significant reduction in the adhesion of leukocytes, in the 
plasma levels of vWF factor, and in lipid peroxidation compared with controls.  
Achieving the localized effect of the drug in blood vessels was the rationale behind 
conjugating 17b-estradiol to dextran with Mw of 2 MDa [156*]. 17b-Estradiol is an estrogen 
with promising cardiac protective effects, however, its applications in this therapeutic area 
are limited by the uncontrolled stimulation of estrogen receptors in the body and the effect on 
coagulation [159]. Therefore, it was conjugated to a very large polymeric carrier to restrict 
the effect of 17b-estradiol in vascular lumens. In vivo bio-distribution studies revealed no 
diffusion of the conjugate into red blood cells, and no evidence of the accumulation of the 
conjugate in the heart, lung, or liver. A long residence time of the conjugate was also noticed, 
with slow renal excretion. Importantly, there was no significant effect of the conjugate on the 
rat’s uterus. Moreover, the conjugate produced myocardial protection of 85% and reduced the 
damage of the myocardial tissue due to coronary ischemic reperfusion by half in 
gonadectomised male Wistar rats.  
Effective treatment of CV diseases with minimised or even removed side effects might be 
achieved using macromolecular prodrugs. This concept offered the use of several effective 
drugs with limited applications. This could be obtained by localising drug effects at defected 
tissues or by improving their water solubility.  
 
2.5. Polymer-drug conjugates as polymer therapeutics for endocrine 
diseases 
In the context of endocrine diseases PDCs have been suggested for hormone replacement 
therapy and diabetes (Table 2). With regards of hormonal replacement therapy, the purpose 
was to improve the water solubility of estradiol, which was obtained by the same mechanism 
that was described in previous sections [160,161].  
For diabetes, however, the purpose of using PDCs was to overcome limitation associated 
with a specific drug: phloridzin. This is a potent, experimental antidiabetic agent, which, 
however, is converted to a toxic metabolite (phloretin) by the hydrolytic effect of β-
glycosidase in the intestine. Conjugation of phloridzin to a macromolecular carrier (g-PGA or 
PAMAM) was achieved through a non-biodegradable bond. The test conjugate significantly 
inhibited intestinal glucose uptake in vivo after oral administration when compared to 
controls. This was likely due to the steric bulk of the polymer minimising hydrolysis of 
conjugated phloridzin by intestinal β-glycosidase enzymes and consequently, retaining its 
activity [162]. However, conjugation reduced the in vitro activity of phloridzin by ca. 90%. 
Moreover, even though the phloretin was entrapped within the backbone of the non-
absorbable polymer, its latent toxicity remained a risk factor for patients who received the 
conjugate for a long time. Therefore, in another study, phloridzin and g-PGA were replaced 
with arbutin (an experimental agent with antidiabetic activity) and PAMAM G3 [164*]. In 
vitro results indicated that the PAMAM-arbutin exhibited an inhibitory effect comparable to 
that of the PAMAM-phloridzin even though the effect of free arbutin was 30 time lower than 
that of free phloridzin. Moreover, in vivo studies indicated the ability of PAMAM-arbutin to 
inhibit uptake of D-glucose despite the free arbutin showing no influence on the induced 
hyperglycaemic effect.  
These applications of PDCs to diabetes are, in our view, of particular interest as they have 
moved away from the standard route of administration of PDCs (i.v.) and are exploring their 
potential for oral administration. This aspect is also further explored in the next section. 
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2.6. Polymer-drug conjugates as polymer therapeutics for digestive 
diseases 
The application of PDC for the treatment of diseases affecting the gastro-intestinal tract is 
a very interesting case of how one of the main weaknesses of this technology has been 
cleverly turned into an advantage. PDCs are generally designed for i.v. administration. This is 
not surprising as their size does not, generally, allow significant absorption to take place in 
the gastro-intestinal tract. This lack of absorption can, however, be exploited, with advantage, 
for diseases of the digestive system, particularly those affecting the lower part of the gastro-
intestinal tract (GIT). 
Ulcerative colitis is a major inflammatory disease of the digestive system which is 
typically treated with corticoids and other NSAIDs [173]. However, an optimum therapeutic 
efficacy of these drugs cannot be obtained as these drugs are often released and absorbed in 
the upper digestive tract, which also results into systemic side effects. Different PDCs were 
prepared with the aim of providing targeted release of the drugs to the colon (Table 2). A 
conjugate of PAMAM G3 and 5-aminosalicylic acid was developed for this purpose. 
PAMAM dendrimers were used in the conjugates due to their negligible absorption after oral 
administration in rats. Azo compounds (PAH or PABA) were used as linkers which could be 
hydrolysed by azoreductase enzymes in the colon, allowing localised release [168]. In vitro 
release studies demonstrated that PAMAM-PAH-5-aminosalicylic acid and PAMAM-PABA-
5-aminosalicylic acid were chemically stable in the gastric homogenate and in buffers at pH 
1.2 and 6.8, and were only negligibly (7.2% and 4.5 %, respectively) released in an 
homogenate of the small intestine.  Further release was detected when PAMAM-PAH-5-
aminosalicylic acid and PAMAM-PABA-5-aminosalicylic acid were incubated in cecal 
content for 12 h (38.2% and 23.5 %, respectively). However, the release of 5-aminosalicylic 
acid from sulfasalazine was faster with 80% release during the first 6 h of incubation. This 
indicated the ability of the conjugate to selectively deliver the drug to the colon without 
premature release in the upper GIT. The same strategy was applied for dexamethasone using 
a mucoadhesive polymer, specifically poly(dimethylamino)ethyl methacrylate (pDEAEMA) 
[172]. The conjugate offered a localised release of the drug in the intestine and retained the 
anti-inflammatory activity of the free dexamethasone 
With their ability to effectively localise the release of drugs at targeted segments of the 
intestine, with prolonged therapeutic effects, macromolecular prodrugs have provided 
opportunities for treating chronic inflammatory diseases of the GIT.   
 
2.7. Polymer-drug conjugates as polymer therapeutics for bone diseases 
Osteoporosis is a common skeletal disease that is related to ageing and menopause. The 
main feature of this chronic metabolic disorder is increased fragility of bones [183]. 
Bisphosphonates (alendronate) and anabolic agents (prostaglandin E1) have showed efficacy 
for treating osteoporosis [184]. Alendronate has been previously used in PDC conjugates, as 
a targeting moiety for bone metastasis, with promising in vivo results [1]. In an extension of 
this application, PDCs were therefore suggested for the treatment of osteoporosis (Table 2). 
These studies mainly focused on reducing unwanted cellular interactions and increasing 
targeting to bone osteoclasts, which mediate bone resorption. 
To reduce the gastric mucosal damage induced by the oral administration of alendronate, a 
PDC was developed for intrapulmonary administration [182*]. In vivo studies in rats showed 
that the conjugate did not cause any significant elevation in total protein and lactate 
dehydrogenase levels in the bronchoalveolar fluid when compared to the free drug, which 
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indicated reduced toxicity of the conjugated alendronate. The conjugate was also 
accompanied with similar therapeutic activity to that of the native drug.   
PDCs of alendronate and prostaglandin E1were also developed using HPMA as a 
polymeric carrier to provide selective targeting of the bone cells. The design of these systems 
depended mainly on using a cathepsin K labile linker (GGProNle) and on using targeting 
moieties: alendronate itself or D-aspartic acid peptide. These studies indicated that the 
conjugates could liberate the drugs mainly in osteoclasts by the hydrolytic effect of cathepsin 
K. Moreover, they gave detailed information about the selectivity of the targeting moieties, 
where the D-aspartic acid peptide was more selective in distinguishing resorption sites, and 
alendronate showed stronger binding and recognition of formation and resorption sites 
[177,179].   
Finally, it is important to highlight a recent study which is based on the expression of 
CD44 receptors on the surface of osteoclasts which mediate the endocytosis of HA (which 
has been previously highlighted in section 2.2), and on the intracellular hydrolysis of HA by 
hyaluronidase. Therefore, pamidronate was conjugated to low (L) and high (H) MW HA. In 
vitro studies indicated that both conjugates showed high selectivity towards osteoclasts 
compared to the free pamidronate. However, the L-HA conjugate was more toxic against the 
cells than the H-HA and the free drug. Interestingly, the L-HA conjugate could localise inside 
osteoclast like cells, while H-HA conjugate adhered to the cell surface and did not exhibit 
any cellular uptake over 12 h [174].  
Age-related bone diseases bring significant challenges. As the aging population is 
progressively increasing, successes in this area, could potentially be particularly impactful. 
 
 
2.8. Polymer-drug conjugates as polymer therapeutics for ocular diseases 
A new area for the application of PDCs was explored within eye related problems. The 
application of macromolecular prodrugs for treating eye related diseases has been studied 
recently. Interestingly, the intravitreal administration was used to apply these systems with 
the intention of enhancing drug accumulation within the defected tissues, and prolonging the 
t1/2 of the drug, Table 2. 
The ability of dendrimers to accumulate in inflamed tissues was also employed to achieve 
selective delivery of intravitreally administered fluocinolone acetonide to the activated retinal 
microglia. The system was developed by conjugating fluocinolone acetonide to PAMAM G4 
dendrimers [185*]. In vivo distribution studies in a Royal College of Surgeon rat model 
revealed the localisation of the dendrimers in activated microglia for 30 days after injection. 
Furthermore, PAMAM-fluocinolone acetonide was significantly more active than the free 
drug. Interestingly, in vitro studies indicated sustained release of fluocinolone acetonide from 
PAMAM-fluocinolone acetonide for 91 days in PBS pH 7.4.  
The rationale for extending the t1/2 was applied for EXP3174 (losartan metabolite), a 
potent angiotensin II receptor type 1 (AT1R) blocker, which has shown activity for treating 
neovascularisation-related retinopathy. However, the intravitreal administration of EXP3174 
to improve its activity is limited by its short t1/2. Therefore, EXP3174 was conjugated to 
PAMAM G5 or an 8 arm branched PEG to improve its therapeutic activity [186]. Although 
the binding affinity of PAMAM G5-EXP3174 was 6-fold greater than that of the 8 arm 
PEG40K-EXP3174, it was 30 times less than that of the free drug. This loss of affinity of 8 
arm PEG40K-EXP3174 could be due to the steric hindrance of the polymeric chain and 
masking the ligand via shroud formation around it by PEG. PAMAM G5-EXP3174 exhibited 
a unique microarchitecture and provided a greater multivalency which enhanced the affinity 
towards the receptors.  
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Intravitreal administration of PDCs has opened new possibilities for treating eye related 
problems. By offering prolonged activity and localised accumulation within the tissues of the 
retina, they could improve the therapeutic efficacy of the drugs and prevent the need for their 
frequent administration.  
 
2.9. Polymer-drug conjugates as polymer therapeutics for wound healing 
and tissue regeneration 
Special consideration has been given recently to applying the concept of polymeric 
carriers to wound-related problems and tissue regeneration. Within these areas, the main 
reason for employing PDCs was to increase the water solubility and the stability of the 
conjugated drugs and to apply the combination therapy (Table 2).  
In a very recent study concerning the application of PDCs for enhancing the recovery of 
spinal cord injury (SCI) [188*], curcumin, a natural anti-inflammatory, was conjugated to 
polyacetal (PA) to improve its poor water solubility and low stability by providing a 
controlled release of the drug. In vitro studies indicated pH-dependent release of curcumin 
from a PA-curcumin conjugate, with the release increasing at lower pH. In vivo studies 
revealed that a single administration of PA-curcumin induced a significant increase in motor 
activity after SCI compared to controls or PA. This was associated with reduced volume of 
cavitation. Furthermore, PA-curcumin reduced astrogliosis (glial scar formation) and 
increased the number of neurons fibres. Importantly, PA-curcumin treatment provided a 
neuroprotective effect accompanied by reduced levels of apoptosis and inflammation. The 
combined therapy of PA-curcumin and epSCi improved the function recovery from chronic 
SCI, where they significantly improved the BBB scores, increased the presence of neurons, 
and reduced the scar area.   
Similarly to what noted for bone diseases, wound healing and tissue regenerations issues 
are expanding, meaning that improvements in these areas could be particularly impactful. 
 
3. Conclusions: perspectives towards the applications of polymer-drug 
conjugates in diseases other than cancer. 
First generation polymer-drug conjugates contained standard cytotoxic agents such as 
doxorubicin and paclitaxel. Recent development in PDCs for cancer saw the emergence of 
PDCs which contained more modern agents acting on specific molecular targets (e.g. 
kinases) and/or used the polymer as a platform to co-deliver two drugs [191]. In all cases, the 
system was applied to cancer therapy and the key rationale was essentially targeting the 
tumour tissue, in order to retain efficacy whilst decreasing toxicity.  
Application of the concept of PDCs to diseases other than cancer has opened a new research 
space in this field. As the various therapeutic applications rely on different rationales, it is 
important to appreciate that with different rationales come different design requirements. 
While all features of polymer-drug conjugates (polymer, drug, linker, and, if present, 
targeting group) are important for the overall therapeutic performance, certain features are 
likely to be more meaningful for diseases than for others. The key design considerations of 
PDCs for each application depend primarily on the biological barriers that the conjugate 
needs to cross to reach the site of action, and on its specific therapeutic target. In Table 3, we 
have therefore summarised the various biological barriers encountered by PDCs within these 
new therapeutic areas and have highlighted which structural feature, in our view, is 
particularly key for successful design for a specific disease. Furthermore, the different 
therapeutic applications are associated with different molecular targets, and as such the 
“journey” of polymer-drug conjugates from the administration site to the final target might be 
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different for each application. These new applications have extended the administration 
routes available to PDCs. While all the traditional PDCs were designed for i.v. 
administration, Movantikâ is on the market for oral administration, and some of the PDC 
studies summarised here have been proposed for other routes (e.g. intraocular, see Table 2). 
Each administration route exposes the PDCs to completely different physiological 
environments. For instance, a PDC administered orally will be exposed to completely 
different biological barriers than one administered i.v. (stomach: low pH presence of 
enzymes; blood: neutral pH and a different pool of enzymes) (Table 3). Therefore, again, it is 
important to consider these needs for each specific case. 
Herein, we have identified similarities and differences for the design of PDCs for 
anticancer and non-cancer applications. There are some general features for the design of 
PDCs that are important for cancer applications as well as for other diseases. However, 
applying the concept of PDCs for a specific disease often requires consideration of specific 
requirements that should be considered on a disease-by-disease basis.  Common properties 
that the polymeric carriers should generally have in all applications are biocompatibility, 
biodegradabability, safety, and good drug loading capacity. The water solubility and 
molecular size of the polymer are other key features for the design of PDCs for cancer, in 
order to enhance the solubility of the chemotherapeutic drug (which are usually hydrophobic 
in nature) and to control the elimination of the conjugate (if the polymer is not biodegradable) 
[192]. Some of these properties have received additional interest when selecting a polymer 
for use in a PDC for diseases other than cancers. For example, the biological degradability 
and the MW of the polymer are important when the aim is to localise the effect of the 
conjugated drug at the site of administration. In other cases, polymers are selected that 
synergise the therapeutic activity of the conjugated drug. Moreover, the tropism of some 
polymeric platforms towards specific cells, tissues or organs is also considered in order to 
achieve specific delivery of the conjugate to the desired site, Tables 2 and 3.  
The second crucial consideration for the design of PDCs is the drug itself. To develop 
an effective conjugate for any therapeutic area, the drug should contain a functional group 
that allow its conjugation and subsequent release at the site of action. Moreover, the drug 
should be stable at the target site against the environmental conditions (e.g. the low pH and 
the lysosomal enzymes if the therapeutic target is an intracellular organelle). Finally, the 
activity of the drug should not be compromised after its release [193*]. For PDCs that are not 
administered systemically, as summarised in Tables 2 and 3, the drug should be stable in the 
biological fluids until it reaches the site of action (e.g.: the synovial fluid, the aqueous fluid of 
the eye).  
The third important component of PDC design is the linker. Generally, there are two 
main properties that the linker should exhibit in order to achieve the required therapeutic 
effect regardless of its application. First, the linker should be stable until the PDC reaches the 
intended site of action (blood stream, extracellular fluids, etc.). In addition, the linker should 
be selectively degraded (chemically or enzymatically) at the intended site to provide a 
targeted delivery of the drug [194]. In some new therapeutic applications, however, 
degradability of the linker is not always required, for example when the aim is to prevent the 
premature release of the drug, or to localise its effects at the intended site by reducing its 
diffusion through the biological membranes or tissues (Tables 2 and 3).  
Finally, the addition of a targeting ligand to the structure of a PDC is not always 
necessary when developing traditional PDCs for treating cancers. This is because these 
polymeric systems largely rely on the EPR effect to achieve passive targeted accumulation 
within tumour tissues compared to the normal tissues which do not show this phenomenon. 
However, some of the applications described in this review, rely on a targeting moiety to 
direct the system towards specific cells and tissues, which, in turn, could potentially 
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maximise the therapeutic efficacy and reduces associated side effects [195,196]. The 
application of PDCs to diseases other than cancers is providing an increase pool of possible 
targeting moieties to provide active targeting, especially in pathologies in which passive 
targeting (EPR or EPR-like) would not occur (Tables 2 and 3).        
In addition to the previously mentioned factors, the importance of additional 
challenges, such as manufacturing (e.g. scaling up, sterilisation requirements, stability issues) 
and differences in patient populations (e.g. expression of a specific target molecule etc.) are 
evident in all of the applications and need careful consideration. 
In this commentary, we have illustrated the breadth of research currently being 
undertaken in the field of PDCs. We have analysed each therapeutic area, and the promising 
results that are emerging, with particular attention on the rationale for using PDCs in these 
new applications and the key considerations for the design of these systems. PDCs are 
intrinsically rather complex systems and, in our view, more PDCs can successfully reach the 
market place only if the complexity of the design of these systems is correctly addressed, and 
specific needs for each therapeutic application are fully appreciated.  
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[23]   
R
4a 
PEG
-vancom
ycin 
D
 (am
ide, carbam
ate)  
N
/A
 
B
acterial 
i.v 
[24]  
Infection: b) A
ntifungal 
R
2 
A
rabinogalactan-am
photericin B
 
D
/H
 (am
ine, im
ine) 
N
/A
 
Fungal  
i.v 
[35] 
R
2 
m
PEG
-am
photericin B
 
D
/E (carbam
ate)  
N
/A
 
Fungal 
N
/A
 
[36] 
R
2 
A
rabinogalactan-am
photericin B
 
D
/H
 (am
ine, im
ine) 
N
/A
 
Fungal 
i.v 
[37] 
R
2 
PEG
-am
photericin B
 
D
/E (carbam
ate, carbonate) 
N
/A
 
Fungal  
i.v 
[38] 
R
2 
A
rabinogalactan-am
photericin B
 
D
/H
 (am
ine) 
N
/A
 
Fungal  
i.v 
[39] 
R
3c 
PEG
-b-poly(L -lysine)-am
photericin B
 
 D
/H
 (im
ine)  
N
/A
 
Fungal 
N
/A
 
[40] 
R
3c 
PEG
-am
photericin B
 
D
/H
 (im
ine)  
N
/A
 
 
i.v 
[41] 
R
3d 
sPEG
-am
photericin B
 
 D
/E (phenyl-b-D
-glucopyranoside)  
N
/A
 
Fungal 
N
/A
 
[42] 
R
3d 
sPEG
-nystatin  
D
/E (phenyl-b-D
-glucopyranoside)  
N
/A
 
Fungal 
i.v 
[43*] 
Infection: c) A
ntiviral 
R
1a  
m
PEG
-zidovudine 
D
/H
 (ester)  
N
/A
 
H
IV
  
p.o 
[50] 
R
1a 
m
PEG
-PC
L-acyclovir 
C
hitosan-PC
L-acyclovir 
D
/H
 (ester) 
N
/A
 
H
SV
-1/2 
N
/A
 
[51] 
R
1a, R
2 
PH
EA
-acyclovir 
D
/H
 (ester)  
N
/A
 
H
SV
-1/2   
p.o/ i.v 
[52] 
R
1a, R
2 
Sulfonated C
hitosan-stavudine 
D
/H
 (ester)  
N
/A
 
H
IV
 
p.o 
[53] 
R
1a, R
4b 
C
hitosan-stavudine 
D
/H
 (phosphoram
idate)  
N
/A
 
H
IV
 
N
/A
 
[54,55] 
R
1a, R
5a 
k-carrageenan-zidovudine 
D
/H
 ester  
N
/A
 
H
IV
 
N
/A
 
[56] 
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R
1b 
b-cyclodextrin-acyclovir 
D
/E (ester) 
N
/A
 
H
SV
-1/2  
N
/A
 
[57] 
R
1b 
Poly(H
EM
A
)-zidovudine 
D
/E (ester)  
N
/A
 
H
IV
 
p.o 
[58] 
R
1b, R
2 
PEG
-acyclovir 
D
/E (ester)  
N
/A
 
H
SV
-1/2  
N
/A
 
[59] 
R
1b, R
2 
PEG
-valacyclovir 
D
/E (am
ine)  
N
/A
 
H
SV
-1/2  
N
/A
 
[59] 
R
1b, R
2 
PEG
-acyclovir 
D
/E (A
m
ide: G
L)  
N
/A
 
H
SV
-1/2  
p.o 
[60] 
R
2, R
4a 
PH
EA
-zidovudine 
D
/E (ester) 
N
/A
 
H
IV
  
p.o 
[61] 
R
2, R
4a  
D
extrin-zidovudine 
D
/E, H
 (ester)  
N
/A
 
H
IV
 
i.v 
[62] 
R
3a 
PEG
-saquinavir 
D
/H
 (ester)  
B
iotin/R
.I.C
K
-Tat 9 
peptide 
H
IV
 
N
/A
 
[63,64] 
R
3a 
C
hitosan -lam
ivudine 
D
/H
 (O
-P)  
Lactobionic acid 
H
B
V
 
N
/A
 
[65] 
R
3a, R
6 
Poly-L -lysine-ribavirin 
D
/H
 (phosphate)  
Latcosam
ine 
H
C
V
 
i.m
 
[66] 
R
3b 
D
extran (25kD
a)-lam
ivudine 
D
/H
 (Ester)  
N
/A
 
H
B
V
 
i.v 
[67] 
R
4a 
C
hitosan-stavudine 
D
/H
 (ester)  
N
/A
 
H
IV
 
N
/A
 
[68] 
R
4a 
m
PEG
-zidovudine 
D
/E (ester)  
N
/A
 
H
IV
 
p.o 
[69] 
R
4a, R
5a 
Sulfated lam
inaripentose-zidovudine 
D
/H
 (ester)  
N
/A
 
H
IV
  
N
/A
 
[70] 
R
6 
PA
A
-ribavirin 
D
/H
 (ester)  
N
/A
 
H
C
V
/H
IV
 
N
/A
 
[71*] 
R
6 
PA
A
-ribavirin, PM
A
A
-ribavirin 
D
/H
 (ester) 
N
/A
 
H
C
V
/H
IV
 
N
/A
 
[72] 
R
6 
PV
P, PH
PM
A
, PA
A
, PM
A
A
/ribavirin 
- 
N
/A
 
H
C
V
/H
IV
 
N
/A
 
[73] 
R
6 
PA
A
-ribavirin 
 PM
A
A
-ribavirin 
D
/H
 (ester)  
N
/A
 
H
C
V
/H
IV
 
N
/A
 
[74] 
Infection: 3) A
ntiprotozoal  
M
odel drug 
D
extran-m
etronidazole 
D
/H
 (ester)  
N
/A
 
A
m
oebic dysentery 
N
/A
 
[78] 
R
1a, R
2 
A
rabinogalactan-am
photericin B
 
D
/H
 (am
ine, im
ine) 
N
/A
 
Leishm
aniasis 
s.c/i.v 
[79] 
R
1a, R
2 
A
rabinogalactan-am
photericin B
 
D
/H
 (am
ine) 
N
/A
 
Leishm
aniasis 
i.v 
[39] 
R
1a, R
4b 
PH
EA
-prim
aquine, PH
PA
-prim
aquine 
D
/H
 (carbam
ate)  
N
/A
 
M
alaria 
p.o 
[80] 
R
3a 
H
PM
A
 copolym
er-N
PC
1161 
D
/E (am
ide: G
FLG
)  
N
-acetyl 
m
annosam
ine 
Leishm
aniasis 
i.v 
[81,82] 
R
3a 
(H
PM
A
-A
m
photericin B
) copolym
er 
D
/E (am
ide: G
FLG
)  
M
annosam
ine 
Leishm
aniasis 
i.v 
[83] 
R
5b 
Poly(H
PM
A
)-am
photericin B
-alendronic 
acid 
D
/E (am
ide: G
FLG
)  
N
/A
 
Leishm
aniasis 
i.v 
[84] 
R
5b 
Polyphosphazenes-prim
aquine-
dihydroartem
isinin 
D
/H
 (O
-P and/or N
-P)  
N
/A
 
M
alaria 
N
/A
 
[85] 
Inflam
m
ation and im
m
une system
 
M
odel drug 
PH
EA
-aspirin 
 D
/H
 (ester) 
N
/A
 
Inflam
m
ation 
N
/A
 
[95] 
M
odel drug 
D
extran-naproxen  
D
/E, H
 (ester)  
N
/A
 
Inflam
m
ation 
i.artic/p.o 
[96,97] 
R
1a 
PH
EA
-naproxen 
D
/H
 (ester)  
N
/A
 
Inflam
m
ation 
p.o 
[98] 
R
1a,b 
Poly (H
EM
A
)-diclofenac 
D
/E, H
 (ester)  
N
/A
 
Inflam
m
ation 
p.o 
[99] 
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R
1a,b 
m
PEG
-ibuprofen 
PA
M
A
M
 G
4-ibuprofen 
D
/E, H
 (ester, am
ide, peptide) 
N
/A
 
Inflam
m
ation 
N
/A
 
[100] 
R
1a, R
2 
V
inyl ether polym
er-ibuprofen/ 
ketoprofen/ naproxen 
D
/H
 (am
ide)  
N
/A
 
Inflam
m
ation 
N
/A
 
[101] 
R
1a, R
5a 
C
hondroitin sulfate-ibuprofen/ 
ketoprofen/ naproxen 
D
/H
 (ester: PEG
)  
N
/A
 
Inflam
m
ation 
p.o 
[102] 
R
2 
PA
M
A
M
 (G
0)-naproxen 
D
/E, H
 (ester)  
N
/A
 
Inflam
m
ation 
p.o 
[103] 
R
2 
PA
M
A
M
 (G
0)-naproxen 
D
/E, H
 (am
ide, ester)  
N
/A
 
Inflam
m
ation 
p.o 
[104] 
R
2 
m
PEG
-tacrolim
us 
D
/E (ester)  
N
/A
 
Im
m
unosuppression 
N
/A
 
[105] 
R
2, R
4b 
A
lginate-curcum
in 
D
/H
 (ester)  
N
/A
 
Inflam
m
ation 
N
/A
 
[106] 
R
2, R
4b 
H
yaluronic acid-curcum
in 
D
/H
 (ester)  
N
/A
 
Inflam
m
ation 
N
/A
 
[107] 
 R
2, R
4b, R
6 
(A
cryl am
ide-dapsone) copolym
er 
N
/A
 (am
ide) 
N
/A
 
Inflam
m
ation 
N
/A
 
[108*] 
R
3a 
PA
M
A
M
 (G
5)-m
ethotrexate 
N
/A
 (ester)  
Folic acid 
R
A
 
i.v 
[109] 
R
3a 
H
yaluronic acid-m
ethotrexate 
D
/H
 (ester) 
H
yaluronic acid 
R
A
 
i.v 
[110] 
R
3a 
PA
M
A
M
 G
5-m
ethotrexate 
D
/E, H
 (ester)  
Folic acid 
R
A
 
i.v 
[111] 
R
3a, R
3e 
LM
W
H
C
-prednisolone  
N
/A
 (am
ide)  
N
/A
 
R
enal inflam
m
ation 
i.v 
[112] 
R
3a, R
5a   
H
yaluronic acid-m
ethotrexate 
D
/E (am
ide: A
snPhePhe)  
H
yaluronic acid 
osteoarthritis 
i.artic 
[113,114] 
R
3b 
PA
M
A
M
 (G
4)-m
ethylprednisolone 
D
/E, H
 (ester: G
lutaric acid) 
N
/A
 
Inflam
m
ation 
N
/A
 
[115] 
R
3b 
PA
M
A
M
 (G
4)-erythrom
ycin 
D
/H
 (ester)  
N
/A
 
Periprosthetic 
inflam
m
ation 
N
/A
 
[22*] 
R
3b 
D
extran-m
ethylprednisolone 
D
/E (ester)  
N
/A
 
Im
m
unosuppression 
i.v 
[116,117*] 
R
3c, R
3e 
H
PM
A
 copolym
er-dexam
ethasone 
D
/H
 (hydrazone)  
N
/A
 
R
A
 
i.v 
[118] 
R
3c, R
3e 
H
PM
A
 copolym
er-dexam
ethasone 
D
/H
 (hydrazone: G
G
)  
N
/A
 
R
A
 
i.v 
[119] 
R
3c 
PA
M
A
M
 (G
3.5)-N
-acetyl cysteine 
PA
M
A
M
 (G
4)-N
-acetyl cysteine 
D
/H
 (disulphide)  
N
/A
 
N
euroinflam
m
ation 
N
/A
 
[120] 
R
3c 
PA
M
A
M
 (G
3.5)-N
-acetyl cysteine 
D
/H
 (disulphide) 
N
/A
 
N
euroinflam
m
ation 
N
/A
 
[121*] 
R
3c 
PA
M
A
M
 (G
4)-N
-acetyl cysteine 
D
/H
 (disulphide) 
N
/A
 
Inflam
m
ation 
N
/A
 
[122] 
R
3c 
PEG
-polyacrylate-naproxen 
O
R
 (phenylboronic ester)  
Phenylboronic ester 
Inflam
m
ation 
N
/A
 
[123] 
R
3e 
Linear cyclodextrin-m
ethylprednisolone 
D
/E, H
 (thioether)  
N
/A
 
R
A
 
i.v 
[124] 
R
4a 
PH
EA
-fenoprofen, PA
H
A
-fenoprofen 
N
/A
 (ester, am
ide) 
N
/A
 
Inflam
m
ation 
N
/A
 
[125] 
R
4a 
PH
EA
-fenoprofen 
D
/E, H
 (ester)  
N
/A
 
Inflam
m
ation 
p.o 
[126] 
R
4c 
PH
EA
-diflunisal, PH
EA
-naproxen, 
PH
EA
-ketoprofen 
D
/E, H
 (ester)  
N
/A
 
Inflam
m
ation 
N
/A
 
[127] 
R
5b 
PEG
-ibuprofen-eugenol 
D
/E, H
 (am
ide, ester)  
N
/A
 
Inflam
m
ation 
p.o 
[128] 
R
6 
PEG
-ibuprofen 
D
/E, H
 (m
ercaptoethyl)  
N
/A
 
Inflam
m
ation 
t-derm
al 
[129] 
N
ervous system
 diseases 
R
2, R
4b 
PH
EA
-L -dopa 
D
/H
 (ester)  
N
/A
 
Parkinson’s disease 
IC
M
D
T 
[141] 
	
32 
R
2, R
4b 
PH
EA
-L -dopa 
D
/H
 (ester)  
N
/A
 
Parkinson’s disease 
N
/A
 
[142] 
R
3c 
PG
A
-doxycycline 
D
/E, H
 (am
ide, ester, am
ino acid) 
N
/A
 
A
m
yloidotic disease 
i.v 
[143*] 
R
4b 
PH
EA
-dopam
ine, SM
A
-dopam
ine 
D
/H
 (am
ide)  
N
/A
 
Parkinson’s disease 
N
/A
 
[144] 
R
6 
PEG
-naloxol 
N
on-biodegradable (ether)  
N
/A
 
O
pioid-induced 
constipation  
p.o 
[145] 
R
6 
PEG
-haloperidol 
N
on-biodegradable (carbam
ate)  
N
/A
 
W
ound healing 
N
/A
 
[146*] 
C
ardiovascular diseases 
R
1a,b 
PH
EA
-gem
fibrozil 
PH
PA
-gem
fibrozil 
D
/E, H
 (ester, am
id)  
N
/A
 
D
yslipidaem
ia and 
atherosclerosis 
N
/A
 
[150,151] 
R
2  
SM
A
 copolym
er-A
H
PP 
D
/H
 (am
ide)  
N
/A
 
H
ypertension 
i.v/p.o 
[152] 
R
2 
PEG
-A
H
PP 
D
/H
 (am
ide)  
N
/A
 
H
ypertension 
i.v 
[153] 
R
3c, R
4c 
PG
A
-A
paf-1 
D
/E (am
ide)  
N
/A
 
I/R
 
N
/A
 
[154] 
R
4b 
PH
EA
-m
ethyl dopa 
D
/H
 (ester)  
N
/A
 
H
ypertension 
N
/A
 
[141] 
R
5a 
PEG
-butanediol m
ononitrate 
D
/H
 (ester: b-glutam
ic acid)  
N
/A
 
I/R
 
i.v 
[155] 
R
6 
D
extran (2 M
D
a)-17b-estradiol 
N
/A
 (am
inocaproic)  
N
/A
 
C
oronary heart 
diseases 
i.v 
[156*] 
E
ndocrine disease 
 
R
2 
PA
H
A
-7b-estradiol 
N
/A
 (carbam
ate) 
N
/A
 
Estrogen replacem
ent 
therapy 
N
/A
 
[160] 
R
2 
PA
H
A
-17b-estradiol 
 PA
H
A
-17b-estradiol valerate 
N
/A
 (ester, carbam
ate) 
N
/A
 
Estrogen replacem
ent 
therapy 
N
/A
 
[161] 
R
4b, R
6 
g-PG
A
-phloridzin 
N
on-biodegradable (w
-am
ino 
triethylene glycol)  
N
/A
 
D
iabetes 
p.o 
[162,163] 
R
4b, R
6 
PA
M
A
M
 (G
3)-phloridzin   
PA
M
A
M
 (G
3)-arbutin 
N
on-biodegradable (w
-am
ino 
triethylene glycol) 
N
/A
 
D
iabetes 
p.o 
[164*] 
D
igestive diseases 
 
R
3d 
D
extran-naproxen  
D
/E, H
 (ester)  
N
/A
 
C
olitis 
p.o 
[165,166] 
R
3d 
D
extran-m
ethylprednisolone 
D
/E, H
 (ester)  
N
/A
 
C
olitis 
p.o 
[167] 
R
3d 
PA
M
A
M
 (G
3)-5-am
inosalicylic acid 
D
/E, H
 (azo bonds) 
N
/A
 
U
lcerative colitis 
p.o 
[168] 
R
3d 
C
hitosan-5-am
inosalicylic acid 
D
/E (am
ide)  
N
/A
 
U
lcerative colitis 
p.o 
[169] 
R
3d 
a/b cyclodextrin-naproxen /sulindac/ 
flurbiprofen 
D
/E, H
 (ester)  
N
/A
 
C
olitis 
p.o 
[170] 
R
3d 
D
extran-budenoside 
D
/E (ester)  
N
/A
 
U
lcerative colitis 
p.o 
[171] 
R
6 
pD
M
A
EM
A
-dexam
ethasone 
D
/H
 (ester)  
N
/A
 
C
olitis 
p.o 
[172] 
B
one diseases 
 
R
3a 
H
yaluronic acid-pam
idronate 
N
/A
 (dihydrazide) 
H
yaluronic acid 
O
steoporosis 
N
/A
 
[174] 
R
3b 
PH
PM
A
-alendronate 
D
/E, H
 (am
ide)  
A
lendronate, 
O
steoporosis 
i.v 
[175] 
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 PEG
-alendronate 
PH
PM
A
-D -(A
sp)8 , PEG
-D -(A
sp)8  
aspartic acid 
peptide 
R
3b, R
3c 
H
PM
A
 copolym
er-D -aspartic acid 
peptide 
D
/E (am
ide: G
G
) 
D -aspartic acid 
peptide 
O
steoporosis 
i.v 
[176] 
R
3b, R
3c 
H
PM
A
 copolym
er-alendronate 
H
PM
A
 copolym
er-D -(A
sp)8  
D
/E (am
ide) 
A
lendronate, 
aspartic acid 
peptide 
O
steoporosis 
i.v 
[177] 
R
3b, R
3d 
H
PM
A
 copolym
er-prostaglandin E
1  
D
/E (am
ide: G
G
PN
le)  
W
ith or w
ithout  
D -aspartic acid 
peptide 
O
steoporosis 
N
/A
 / i.v 
[178–180] 
R
3b, R
3d 
H
PM
A
 copolym
er-alendronate 
D
/E (am
ide: G
G
PN
le)  
A
lendronate 
O
steoporosis 
i.v 
[181] 
R
6 
PEG
-alendronate  
N
/A
 (am
ide) 
A
lendronate 
O
steoporosis 
i.pulm
on 
[182*] 
O
cular diseases 
 
R
1a, R
3b 
PA
M
A
M
 (G
4)-fluocinolone 
D
/H
 (ester: glutaric acid)  
N
/A
 
M
acular degeneration 
and retinitis 
pigm
entosa 
i.vitre 
[185*] 
R
4b 
B
ranched PEG
-EX
P3174 
PA
M
A
M
 (G
5)-EX
P3174 
N
/A
 (am
ide) 
N
/A
 
R
etinal 
neovascularization 
i.vitre 
[186] 
 
 
 
 
 
 
 
W
ound healing and tissue regeneration 
R
2 
C
hitosan-kartogenin 
D
/H
 (am
ide)  
N
/A
 
O
steoarthritis 
i.a 
[187] 
R
2, R
4b 
Polyacetal-curcum
in 
D
/H
 (ether)  
N
/A
 
Traum
atic spinal cord 
injury 
i.t 
[188*] 
R
5a 
PA
M
A
M
 (G
3.5)-D
(+) glucosam
ine,  
PA
M
A
M
 (G
3.5)-D
(+) glucosam
ine 6-
sulfate 
N
/A
 (am
ide) 
N
/A
 
Prevent scar 
form
ation  
i.p/s-
conjunc  
[189] 
R
6  
C
hitosan-ED
TA
 
N
/A
 (am
ide) 
N
/A
 
W
ound dressing  
N
/A
 
[190] 
a. R
ationales defined in Table 1. 
b. B
iodegradability is defined as degradable (D
) or non-biodegradable (N
D
); M
echanism
s of degradability are indicated as enzym
e (E) or hydrolysis (H
) or redox 
(redox) or oxidation response (O
R
).  
c. R
oute of adm
inistration (R
O
A
); Intracerebral m
icrodialysis technique (IC
M
D
T); Intraarticular (i.artic); Intraperitoneal (i.p); intrapulm
onary (i.pulm
on); Intrathecal  
(i.t); Intravenous(i.v); intravitreal: (i.vitre). oral: (p.o); subconjunctival: (s.conjunc); subcutaneous: (s.c); transderm
al: (t.derm
al).  
d. N
ot applicable/not stated (N
/A
). 
*: The aim
 of the study w
as to evaluate erythrom
ycin for the anti-inflam
m
atory effect.  
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T
able 3. A
 sum
m
ary of the biological barriers for the application of PD
C
s for diseases other than cancer and the key considerations for their design. 
         B
iological 
         barriers 
   D
iseases 
Step 1: A
bsorption 
(From
 adm
inistration 
site to the blood)  
Step 2: D
istribution  
(From
 the blood to the 
site of action)  
Step 3: C
ellular 
pharm
acokinetics 
(C
ellular internalization 
and trafficking) 
 
K
ey specific considerations in designing PD
C
s a 
      
 
 
 
D
rug 
     
L
inker 
Polym
er 
 
 
T
argeting m
oiety 
B
acterial 
infections 
G
IT pH
 and enzym
es b 
B
lood vessel endothelia 
to the infected site  
(except for 
septicaem
ia) 
Transportation to 
phagosom
al vacuoles and 
cytoplasm
 
M
ultidrug resistance 
B
inding to pathogen cells 
after release 
Intracellularly stable  
E
nzym
atic/pH
 labile  
M
W
 of the 
polym
er  
T
argetability of 
the polym
eric 
carrier 
R
eceptor 
recognized m
oiety 
Fungal 
infections 
N
/A
 
B
lood vessel endothelia 
to the infected site  
Transportation to the 
fungal cell 
M
ultidrug resistance 
B
inding to pathogen 
m
em
brane after release 
E
nzym
atic/pH
 labile  
H
ydrophilicity of 
the polym
er 
- 
V
iral infections 
G
IT pH
 and enzym
es b 
B
lood vessel endothelia 
to the infected site  
R
B
C
s interaction  
Intracellular transportation  
(cell m
em
brane 
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Intracellular transportation  
 
Intracellularly stable 
R
etain activity w
hile 
conjugated 
Enzym
atic/pH
 labile  
E
nzym
atic/pH
 
stable 
M
W
 of the 
polym
er 
- 
C
ardiovascular 
diseases 
G
IT pH
 and enzym
es b 
B
lood vessel endothelia  
N
/A
 
Stable in G
IT 
B
inding to specific 
receptors after release 
E
nzym
atic/pH
 labile 
 
M
W
 of the 
polym
er   
- 
Enzym
e
G
olgi
M
itochondrion
	
35 
a: B
old font indicates the key part of the design of PD
C
s for a specific rationale. 
b: In som
e of studies for each application, the PD
C
s w
ere evaluated as oral drug delivery system
s. 
N
A
: N
ot applicable.  
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raphical abstract. N
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er-drug. 
